Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Receivables (2021 - 2025)

PAVmed has reported Receivables over the past 5 years, most recently at $15000.0 for Q4 2025.

  • Quarterly results put Receivables at $15000.0 for Q4 2025, down 16.67% from a year ago — trailing twelve months through Dec 2025 was $15000.0 (down 16.67% YoY), and the annual figure for FY2025 was $15000.0, down 16.67%.
  • Receivables for Q4 2025 was $15000.0 at PAVmed, up from $3000.0 in the prior quarter.
  • Over the last five years, Receivables for PAVM hit a ceiling of $219000.0 in Q2 2024 and a floor of $3000.0 in Q2 2025.
  • Median Receivables over the past 5 years was $33500.0 (2022), compared with a mean of $64750.0.
  • Biggest five-year swings in Receivables: surged 434.15% in 2024 and later crashed 98.63% in 2025.
  • PAVmed's Receivables stood at $200000.0 in 2021, then crashed by 91.5% to $17000.0 in 2022, then surged by 258.82% to $61000.0 in 2023, then crashed by 70.49% to $18000.0 in 2024, then decreased by 16.67% to $15000.0 in 2025.
  • The last three reported values for Receivables were $15000.0 (Q4 2025), $3000.0 (Q3 2025), and $3000.0 (Q2 2025) per Business Quant data.